Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono Set for Japan Filing of SK Bio’s Epilepsy Med in FY2025
Ono Pharmaceutical said on December 10 that its South Korean partner SK Biopharmaceuticals’ antiepileptic drug cenobamate delivered positive results in an Asian PIII program. The Japan firm, which has the domestic rights to the compound, is now poised to file…
To read the full story
Related Article
- Ono Files SK Bio’s Epilepsy Med Cenobamate in Japan
October 1, 2025
- Ono Licenses Epilepsy Med from South Korean Biopharma
October 14, 2020
BUSINESS
- Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Expert Highlights Subcutaneous Benefits of Rybrofaz in Lung Cancer
April 6, 2026
- NEC Bio, Transgene Strike Licensing Deal for Cancer Vaccine
April 6, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…